共 98 条
[1]
Cuchel M(2014)Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial Hypercholesterolaemia of the European Atherosclerosis Society Eur Heart J 35 2146-2157
[2]
Bruckert E(2007)Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 148-156
[3]
Ginsberg HN(2015)Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial Lancet 385 341-350
[4]
Raal FJ(2012)Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia J Clin Lipidol 6 331-339
[5]
Santos RD(2017)Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor Lomitapide in patients with homozygous familial hypercholesterolemia Circulation 136 332-335
[6]
Hegele RA(2013)Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 40-46
[7]
Kuivenhoven JA(2016)Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia J Clin Lipidol. 10 1011-1021
[8]
Nordestgaard BG(undefined)undefined undefined undefined undefined-undefined
[9]
Descamps OS(undefined)undefined undefined undefined undefined-undefined
[10]
Steinhagen-Thiessen E(undefined)undefined undefined undefined undefined-undefined